Tags

Type your tag names separated by a space and hit enter

Endocannabinoid system and cardio-metabolic risk.
Med J Malaysia. 2008 Oct; 63(4):348-50; quiz 351.MJ

Abstract

Recent research in bio-medical science has shown an integral role of endocannabinoid system (ECS) in determining cardio-metabolic risk of human body. The mechanism is mediated through binding of endocannabinoids at the CB1 receptors. The stimulation of CB1 receptor in the brain is believed to control and mediate the effects on appetite. In normal physiology, CB1 receptors activation is responsible for energy homeostasis, govern emotions and behaviors such as anxiety, fear, appetite, food and water intake. CB1 receptors also found in peripheral tissues like liver, pancreas, skeletal muscles and adipose tissues, which play an important role in lipid and glucose metabolism. Over-activation of ECS is associated with various metabolic diseases such as dyslipidemia, insulin resistance, lipogenesis, excessive weight gain and increasing intra-abdominal obesity. All these events lead to increased cardiovascular risk. Use of selective CB1 receptor blocker such as rimonabant has shown to reduced waist circumference, better glycemic control, lower triglyceride levels, raise HDL cholesterol and over all reduction in total body fat. This drug has been recommended for patients with metabolic syndrome.

Authors+Show Affiliations

Department of Family Medicine, International Medical University Malaysia, Jalan Rasah, Seremban 70300, Malaysia. Kengyin_loh@imu.edu.myNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19385504

Citation

Loh, K Y., and S T. Kew. "Endocannabinoid System and Cardio-metabolic Risk." The Medical Journal of Malaysia, vol. 63, no. 4, 2008, pp. 348-50; quiz 351.
Loh KY, Kew ST. Endocannabinoid system and cardio-metabolic risk. Med J Malaysia. 2008;63(4):348-50; quiz 351.
Loh, K. Y., & Kew, S. T. (2008). Endocannabinoid system and cardio-metabolic risk. The Medical Journal of Malaysia, 63(4), 348-50; quiz 351.
Loh KY, Kew ST. Endocannabinoid System and Cardio-metabolic Risk. Med J Malaysia. 2008;63(4):348-50; quiz 351. PubMed PMID: 19385504.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Endocannabinoid system and cardio-metabolic risk. AU - Loh,K Y, AU - Kew,S T, PY - 2009/4/24/entrez PY - 2009/4/24/pubmed PY - 2009/5/6/medline SP - 348-50; quiz 351 JF - The Medical journal of Malaysia JO - Med J Malaysia VL - 63 IS - 4 N2 - Recent research in bio-medical science has shown an integral role of endocannabinoid system (ECS) in determining cardio-metabolic risk of human body. The mechanism is mediated through binding of endocannabinoids at the CB1 receptors. The stimulation of CB1 receptor in the brain is believed to control and mediate the effects on appetite. In normal physiology, CB1 receptors activation is responsible for energy homeostasis, govern emotions and behaviors such as anxiety, fear, appetite, food and water intake. CB1 receptors also found in peripheral tissues like liver, pancreas, skeletal muscles and adipose tissues, which play an important role in lipid and glucose metabolism. Over-activation of ECS is associated with various metabolic diseases such as dyslipidemia, insulin resistance, lipogenesis, excessive weight gain and increasing intra-abdominal obesity. All these events lead to increased cardiovascular risk. Use of selective CB1 receptor blocker such as rimonabant has shown to reduced waist circumference, better glycemic control, lower triglyceride levels, raise HDL cholesterol and over all reduction in total body fat. This drug has been recommended for patients with metabolic syndrome. SN - 0300-5283 UR - https://www.unboundmedicine.com/medline/citation/19385504/Endocannabinoid_system_and_cardio_metabolic_risk_ L2 - http://www.e-mjm.org/2008/v63n4/Endocannabinoid_System.pdf DB - PRIME DP - Unbound Medicine ER -